Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Completed · Phase 2 · Has a placebo group

Conditions studied: Dyskinesias, Drug-induced

In brief

This study will assess the safety, tolerability and efficacy of AQW051 in treating moderate to severe L-dopa induced dyskinesias (movement disorders) in patients with Parkinson's disease.

Key facts

Study ID

NCT01474421

Run by

Novartis Pharmaceuticals

People needed

71

Starts

2011-09-15

Expected to finish

2013-02-21

Last updated by the study team

2020-12-24

Who can join

Age: 30 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with Parkinson's disease
• Patients with dyskinesias for at least 3 months
• Patients with moderate to severe dyskinesias
• Patients on L-dopa treatment for at least 3 years

You may not qualify if…

• Patients with atypical Parkinson's disease
• Patients who have had prior surgery for Parkinson's disease
• Patients who are cognitively impaired, have psychosis, have confusional states or hallucinate
• Patients who received neuroleptics or anti-psychotics within 2 months
• Women of child-bearing potential
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Investigative Site — Sacramento, California, United States
• Novartis Investigative Site — Manhasset, New York, United States
• Novartis Investigative Site — Cincinnati, Ohio, United States
• Novartis Investigative Site — Cleveland, Ohio, United States
• Novartis Investigative Site — Bron, France
• Novartis Investigative Site — Clermont Fd, France
• Novartis Investigative Site — Lille, France
• Novartis Investigative Site — Marseille, France
• Novartis Investigative Site — Montpellier, France
• Novartis Investigative Site — Nantes, France
• Novartis Investigative Site — Paris, France
• Novartis Investigative Site — Pessac, France
• Novartis Investigative Site — Poitiers, France
• Novartis Investigative Site — Strasbourg, France
• Novartis Investigative Site — Toulouse, France
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Dresden, Germany
• Novartis Investigative Site — Gera, Germany
• Novartis Investigative Site — Haag, Germany
• Novartis Investigative Site — Kassel, Germany
• Novartis Investigative Site — Marburg, Germany
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — Tübingen, Germany
• Novartis Investigative Site — Roma, RM, Italy

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.